ReviewJournal of medical toxicology : official journal of the American College of Medical Toxicology2016
Naltrexone: Not Just for Opioids Anymore.
Review in Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Comparative Effectiveness of Naltrexone Formulations in Alcohol Use Disorder: An Updated Meta-Analysis.Psychopharmacology bulletin · 2026Pooled it
- Dissolving Microneedles with Smart Design-A Tool for Enhancing Skin Permeation of Naltrexone Hydrochloride.Molecules (Basel, Switzerland) · 2026Article
- Exploring the association between sweet liking and treatment response to naltrexone in patients with alcohol use disorder.The international journal of neuropsychopharmacology · 2026Article
- Acute Olfactory Hypersensitivity to Opium and Cannabis Following Naltrexone Administration: A Rare Case Report.Addiction & health · 2026Article
- Off-label and investigational drugs in the treatment of gambling disorder: a critical review.Frontiers in pharmacology · 2026Review
- Article
- Oxytocin as a treatment for alcohol use disorder and heavy drinking: A narrative review.Experimental and clinical psychopharmacology · 2024Review
- Foundations for a Personalized Psycho-Oncology: The State of the Art.Journal of personalized medicine · 2024Review
- Bioabsorbable, subcutaneous naltrexone implants mitigate fentanyl-induced respiratory depression at 3 months-A pilot study in male canines.Physiological reports · 2024Article
- Fentanyl-Type Antagonist of the μ-Opioid Receptor: Important Role of Axial Chirality in the Active Conformation.Journal of medicinal chemistry · 2024Article
- Neuroprotective effects of naltrexone in a mouse model of post-traumatic seizures.Scientific reports · 2024Article
- Review
- Opioid-positive urine drug screen during treatment with oral naltrexone and the clinical implications.The mental health clinician · 2024Article
- Review
- Loss of Consciousness After Naltrexone Implantation: A Case Report.Turk psikiyatri dergisi = Turkish journal of psychiatry · 2024Article
- A Guide to Expanding the Use of Buprenorphine Beyond Standard Initiations for Opioid Use Disorder.Drugs in R&D · 2023Review
- Insights into the Current and Possible Future Use of Opioid Antagonists in Relation to Opioid-Induced Constipation and Dysbiosis.Molecules (Basel, Switzerland) · 2023Review
- Thermosensitive biomaterial gels with chemical permeation enhancers for enhanced microneedle delivery of naltrexone for managing opioid and alcohol dependency.Biomaterials science · 2023Article
- Opiate Antagonists for Chronic Pain: A Review on the Benefits of Low-Dose Naltrexone in Arthritis versus Non-Arthritic Diseases.Biomedicines · 2023Review
- Shifting the sociometer: opioid receptor blockade lowers self-esteem.Social cognitive and affective neuroscience · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Naltrexone is a semi-synthetic opioid with competitive antagonist activity at mu opioid receptors. Its efficacy has been demonstrated in the treatment of alcohol and opioid dependence, but adherence to daily dosing has been recognized as a factor limiting long-term effectiveness. Recently, a long-acting injectable formulation of naltrexone has received FDA-approval for treating alcohol and opioid dependence. This article reviews the pharmacology of naltrexone, the current evidence supporting the use of extended-release naltrexone, and the clinical challenges in the induction of patients to this medication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.